Gene editing technologies such as CRISPR-Cas9 provide potential for the enhancement of human sensory functions, but their application involves a complex balance of science, ethics, and safety. The following is an objective analysis based on current scientific cognition： ###1. Scientific feasibility 1. **Visual enhancement** -Targeted gene: The modification of OPN1LW/OPN1MW (opsin gene) can extend the recognition range of the visible spectrum, and the infrared perception ability of mice has been realized in animal experiments. -Retinal gene therapy: RPE65 gene repair for the treatment of hereditary eye diseases has been approved by the FDA, laying the technical foundation for functional enhancement. 2. **Auditory optimization** -Internal hair cell regeneration: By editing regulatory genes such as Atoh1, it is theoretically possible to repair or increase the hair cells of the cochlea. Mouse models have shown partial success. -Regulation of voltage-gated ion channels (such as KCNQ4) may lower the auditory threshold. ###2. Technical challenges 1. **Delivery system restrictions** -The efficiency of retinal targeting is about 60-70%, while the delivery efficiency of inner ear tissue is less than 30% (2022 "Nature Nanotechnologies" data) 2. **Off-target effect** -Even if the off-target rate of 0.1% is in the sensory nerve tissue, it may cause abnormal nerve conduction (such as hallucinations, tinnitus). ###3. Ethical safety framework 1. **International norms** -The Taipei Declaration of the World Medical Association expressly prohibits non-therapeutic editing of human germ Cells -NIH prohibits funding for human sensory enhancement research (fiscal year 2023 budget description) 2. **Risk-benefit ratio** -The risk of gene therapy for the treatment of blindness is acceptable, but the enhanced vision of healthy people may lead to a 3-5-fold increase in the risk of photosensitive epilepsy (theoretical model) ###4. Realistic application path 1. **Priority areas** -Functional restoration of people with disabilities (such as cochlear implants combined with gene therapy) -Special occupational needs (such as pilots' night vision ability) need to be realized through non-hereditary somatic cell editing 2. **Technological development stage** -Animal model research stage (Harvard University successfully enabled mice to obtain ultraviolet vision in 2023) -It is expected that preclinical studies will require at least 7-10 years of safety verification It is recommended to pay attention to the dynamics of authoritative institutions： -International Gene Editing Summit (held every three years) -Update of the WHO regulatory framework for Human Genome Editing -Progress of approval of somatic cell editing therapy by national Food and drug administrations Any sensory enhancement research must follow a clear boundary between "treatment" and "enhancement" and be conducted in a controlled environment such as a biosafety level 4 laboratory. At present, the sensory enhancement of healthy people is still a restricted area of scientific research, and related technologies should be prioritized for the medical needs of people with disabilities.